pass it to all
TORONTO – A single dose of a U.S.-designed Ebola vaccine may be protective against the disease, a new study suggests. But the research also appears to indicate that dose will have to be relatively large, which may present problems for the vaccine.
The study found that people who got the higher of two doses tested in the trial developed immune responses that look similar to those seen in vaccinated non-human primates who survive exposure to what should have been lethal doses of Ebola. Many of them also developed mild to moderate side-effects.
The vaccine was created by scientists at the U.S. National Institute of Allergy and Infectious Diseases and is being developed by Pharma giant GSK, formerly known as GlaxoSmithKline. The study was published online Wednesday by the New England Journal of Medicine.
Dr. Anthony Fauci, director of the…
View original post 885 more words